Ken Griffin Bio Atla, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.17 - $2.05 $2,574 - $4,510	-2,200 Reduced 81.48%	500 $0
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $23,975 - $68,600	-17,500 Reduced 86.63%	2,700 $3,000
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $12,784 - $23,528	6,800 Added 50.75%	20,200 $69,000
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $4,826 - $12,084	-3,800 Reduced 22.09%	13,400 $32,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $18,870 - $34,077	11,100 Added 181.97%	17,200 $29,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $24,621 - $33,669	-8,700 Reduced 58.78%	6,100 $18,000
Q1 2023 May 15, 2023	SELL	$2.3 - $8.25 $77,050 - $276,375	-33,500 Reduced 69.36%	14,800 $39,000
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $133,977 - $234,513	-21,300 Reduced 30.6%	48,300 $398,000
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $99,372 - $401,206	33,800 Added 94.41%	69,600 $536,000

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.5M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.